HOME › Research Insight › New Product Launches Was the Key Growth Strategy in the Epigenetics Market between 2011 and 2014
New Product Launches Was the Key Growth Strategy in the Epigenetics Market between 2011 and 2014
The major players in the epigenetics market include Abcam (U.K.), Active Motif (U.S.), Diagenode (Belgium), EMD Millipore (U.S.), Illumina (U.S.), New England Biolabs (U.S.), QIAGEN (Netherlands), Sigma-Aldrich (U.S.), Thermo Fisher Scientific (U.S.), and Zymo Research (U.S.).
Epigenetics finds applications in oncology, drug discovery, developmental biology, and research of metabolic and genetic disorders. Rapid growth in the research interest in oncology, along with growing partnerships between biotechnology and pharmaceutical companies for the development of epigenetics-based products, will drive the growth of the global epigenetics market.
The global epigenetics market is a growing market. An analysis of market developments between 2011 and 2014 revealed that new product launches was the most important growth strategy employed by market leaders in this period. This strategy was adopted by all players in this market, except Active Motif (U.S.), which did not launch any new products between 2011 and 2014.
The other important growth strategies adopted by players in this market were agreements, collaborations, joint ventures and partnerships. These strategies were adopted by players to gain immediate technological competency and widen their geographic presence. In 2011–2014, these strategies were adopted by all players except Abcam (U.K.), Active Motif (U.S.), Thermo Fisher Scientific (U.S.), and Zymo Research (U.S.).
Epigenetics Market by Product (Modifying Enzymes, DNA Polymerase, Acetylase, Methyltransferase, Instruments & Consumables, Kit, Bisulphite Conversion Kit, Reagents), Research Area (Developmental Biology, Oncology) & by End User - Global Forecast to 2019
North - Dominion Plaza,
Suite 800, Dallas, TX 75252